https://biotechdocket.com 2026-06-15T22:59:29Z https://biotechdocket.com/articles/the-docket-a-busy-week-of-biotech-patent-grants 2026-06-14 https://biotechdocket.com/articles/by-the-numbers-crispr-filing-velocity 2026-06-13 https://biotechdocket.com/articles/company-primer-regeneron-eylea-patent-estate 2026-06-12 https://biotechdocket.com/articles/mrna-and-lipid-nanoparticles-explained 2026-06-11 https://biotechdocket.com/articles/what-is-rna-interference-explained 2026-06-11 https://biotechdocket.com/articles/cliff-watch-vertex-cf-franchise-competition 2026-06-10 https://biotechdocket.com/articles/antibodies-and-biosimilars-explained 2026-06-09 https://biotechdocket.com/articles/crosswalk-vertex-crispr-casgevy-patents 2026-06-08 https://biotechdocket.com/articles/what-is-the-difference-patent-grant-vs-application 2026-06-06 https://biotechdocket.com/articles/crispr-explained-what-the-broad-patent-claims 2026-06-03 https://biotechdocket.com/articles/reality-check-glp-1-patent-cliff-math 2026-05-28 https://biotechdocket.com/articles/glp-1-explained-how-tirzepatide-works 2026-05-18 https://biotechdocket.com/articles/modality-explained-rna-guided-gene-editing-2020 2020-03-12 https://biotechdocket.com/articles/by-the-numbers-where-glp-1-patents-pointed-2020 2020-09-08 https://biotechdocket.com/articles/crosswalk-anti-vegf-eye-disease-patent-thicket-2020 2020-11-19 https://biotechdocket.com/articles/modality-explained-mrna-lipid-nanoparticles-2021 2021-04-14 https://biotechdocket.com/articles/reality-check-the-mrna-platform-was-already-broad-2021 2021-07-22 https://biotechdocket.com/articles/company-primer-genentech-anti-vegf-antibody-engineering-2021 2021-10-07 https://biotechdocket.com/articles/modality-explained-multi-receptor-incretin-drugs-2022 2022-06-15 https://biotechdocket.com/articles/by-the-numbers-crispr-shifts-from-tools-to-therapies-2022 2022-09-13 https://biotechdocket.com/articles/crosswalk-crispr-sickle-cell-from-patent-to-therapy-2023 2023-05-18 https://biotechdocket.com/articles/modality-explained-antibody-drug-conjugates-2023 2023-08-10 https://biotechdocket.com/articles/reality-check-glp-1-patents-everyone-not-named-lilly-novo-2023 2023-11-09 https://biotechdocket.com/articles/modality-explained-prime-editing-2024 2024-03-21 https://biotechdocket.com/articles/cliff-watch-vertex-cftr-patents-keep-issuing-2024 2024-12-17 https://biotechdocket.com/articles/crosswalk-novo-glp-1-amylin-co-agonist-2024 2024-08-06 https://biotechdocket.com/articles/crosswalk-lilly-incretin-grants-2025 2025-07-22 https://biotechdocket.com/articles/modality-explained-sirna-gene-silencing-2025 2025-03-27 https://biotechdocket.com/articles/by-the-numbers-crispr-patents-diversify-cas-enzymes-2025 2025-10-23 https://biotechdocket.com/articles/reality-check-tirzepatide-compounding-patents-2025 2025-12-04 https://biotechdocket.com/articles/modality-explained-what-an-endonuclease-is-2020 2020-06-25 https://biotechdocket.com/articles/crosswalk-kodiak-dual-antagonist-eye-drug-2021 2021-08-12 https://biotechdocket.com/articles/by-the-numbers-mrna-filings-beyond-the-vaccine-2021 2021-12-08 https://biotechdocket.com/articles/crosswalk-broad-institute-still-anchors-crispr-2022 2022-07-12 https://biotechdocket.com/articles/reality-check-everyone-files-multi-agonist-peptides-2022 2022-09-27 https://biotechdocket.com/articles/modality-explained-aav-gene-therapy-vectors-2023 2023-06-22 https://biotechdocket.com/articles/by-the-numbers-adc-filings-surge-2023 2023-08-23 https://biotechdocket.com/articles/modality-explained-bispecific-antibodies-2024 2024-04-02 https://biotechdocket.com/articles/by-the-numbers-prime-editing-filings-mature-2024 2024-07-04 https://biotechdocket.com/articles/cliff-watch-glp-1-cliff-is-about-formulation-2024 2024-10-31 https://biotechdocket.com/articles/modality-explained-crispr-type-v-enzymes-2025 2025-10-23 https://biotechdocket.com/articles/crosswalk-moderna-mrna-delivery-chemistry-2025 2025-06-10 https://biotechdocket.com/articles/by-the-numbers-sirna-delivery-arms-race-2025 2025-10-30 https://biotechdocket.com/articles/company-primer-eli-lilly-incretin-estate-2025 2025-12-16 https://biotechdocket.com/articles/reality-check-aav-gene-therapy-economics-2023 2023-06-29 https://biotechdocket.com/articles/modality-explained-fetal-hemoglobin-switch-2023 2023-12-07 https://biotechdocket.com/articles/reality-check-bispecific-antibody-hype-2024 2024-04-19 https://biotechdocket.com/articles/crosswalk-mrna-manufacturing-is-the-moat-2021 2021-09-23 https://biotechdocket.com/articles/modality-explained-co-agonist-peptides-2022 2022-10-11 https://biotechdocket.com/articles/cliff-watch-incretin-method-of-use-patents-2025 2025-05-13 https://biotechdocket.com/articles/filing-read-what-lilly-10k-says-incretin-supply-2026 2026-03-04 https://biotechdocket.com/articles/by-the-numbers-lilly-revenue-doubled-2023-2025 2026-05-11 https://biotechdocket.com/articles/reality-check-moderna-rd-outruns-cash-2026 2026-04-08 https://biotechdocket.com/articles/crosswalk-who-controls-casgevy-crispr-vertex-filings-2026 2026-06-02 https://biotechdocket.com/articles/cliff-watch-regeneron-says-eylea-faces-significant-competition-2026 2026-02-25 https://biotechdocket.com/articles/anatomy-vertex-journavx-non-opioid-pain-filings-2026 2026-03-19 https://biotechdocket.com/articles/by-the-numbers-vertex-revenue-climbs-past-12-billion-2025 2026-04-22 https://biotechdocket.com/articles/reality-check-novo-semaglutide-pricing-pressure-filings-2026 2026-05-27 https://biotechdocket.com/articles/modality-explained-moderna-respiratory-vaccine-franchise-2026 2026-06-09 https://biotechdocket.com/articles/by-the-numbers-rd-intensity-lilly-vertex-moderna-2025 2026-05-20 https://biotechdocket.com/articles/company-primer-crispr-therapeutics-from-the-filings-2026 2026-04-15 https://biotechdocket.com/articles/the-docket-what-six-biotech-filings-say-about-2026 2026-06-12 https://biotechdocket.com/articles/risk-factor-read-tirzepatide-was-still-phase-iii-2020 2020-11-04 https://biotechdocket.com/articles/modality-explained-what-crispr-therapeutics-was-building-2020 2020-02-19 https://biotechdocket.com/articles/filing-read-modernas-pipeline-beyond-the-vaccine-2021 2021-03-04 https://biotechdocket.com/articles/risk-factor-read-tirzepatide-submitted-not-approved-2021 2021-11-01 https://biotechdocket.com/articles/modality-explained-how-mrna-medicines-work-2022 2022-03-03 https://biotechdocket.com/articles/crosswalk-who-pays-and-who-profits-exa-cel-2022 2022-11-04 https://biotechdocket.com/articles/filing-read-the-50-50-split-behind-casgevy-2023 2023-11-10 https://biotechdocket.com/articles/cliff-watch-regeneron-says-it-depends-on-eylea-2023 2023-02-10 https://biotechdocket.com/articles/cliff-watch-eylea-and-eylea-hd-face-significant-competition-2024 2024-02-09 https://biotechdocket.com/articles/filing-read-what-powers-vertexs-cf-franchise-2024 2024-02-20 https://biotechdocket.com/articles/by-the-numbers-what-novos-2024-annual-filing-revealed-2025 2025-02-10 https://biotechdocket.com/articles/reality-check-the-eylea-transition-is-still-a-risk-2025 2024-11-04